Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial.
Bemelman FJ, de Fijter JW, Kers J, Meyer C, Peters-Sengers H, de Maar EF, van der Pant KA, de Vries AP, Sanders JS, Zwinderman A, Idu MM, Berger S, Reinders ME, Krikke C, Bajema IM, van Dijk MC, Ten Berge IJ, Ringers J, Lardy J, Roelen D, Moes DJ, Florquin S, Homan van der Heide JJ. Bemelman FJ, et al. Among authors: moes dj. Am J Transplant. 2017 Apr;17(4):1020-1030. doi: 10.1111/ajt.14048. Epub 2016 Oct 17. Am J Transplant. 2017. PMID: 27639190 Free article. Clinical Trial.
Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, Vinks S, Wieland E, Bornemann-Kolatzki K, Brunet M, de Winter B, Dieterlen MT, Elens L, Ito T, Johnson-Davis K, Kunicki PK, Lawson R, Lloberas N, Marquet P, Millan O, Mizuno T, Moes DJAR, Noceti O, Oellerich M, Pattanaik S, Pawinski T, Seger C, van Schaik R, Venkataramanan R, Walson P, Woillard JB, Langman LJ. Masuda S, et al. Among authors: moes djar. Ther Drug Monit. 2024 Sep 25. doi: 10.1097/FTD.0000000000001250. Online ahead of print. Ther Drug Monit. 2024. PMID: 39331837
Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy.
Leegwater E, Baidjoe L, Wilms EB, Visser LG, Touw DJ, de Winter BCM, de Boer MGJ, van Paassen J, van den Berg CHSB, van Prehn J, van Gelder T, Moes DJAR. Leegwater E, et al. Among authors: moes djar. Clin Pharmacol Ther. 2025 Jan;117(1):184-192. doi: 10.1002/cpt.3421. Epub 2024 Aug 15. Clin Pharmacol Ther. 2025. PMID: 39148353 Free PMC article.
An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab.
Kicken MP, Deenen MJ, Moes DJAR, Hendrikx JJMA, van den Borne BEEM, Dumoulin DW, van der Wekken AJ, van den Heuvel MM, Ter Heine R. Kicken MP, et al. Among authors: moes djar. Target Oncol. 2024 Sep;19(5):779-787. doi: 10.1007/s11523-024-01087-4. Epub 2024 Jul 31. Target Oncol. 2024. PMID: 39085452 Free PMC article.
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.
Meertens M, Giraud EL, van der Kleij MBA, Westerdijk K, Guchelaar NAD, Bleckman RF, Rieborn A, Imholz ALT, Otten HM, Vulink A, Los M, Hamberg P, van der Graaf WTA, Gelderblom H, Moes DJAR, Broekman KE, Touw DJ, Koolen SLW, Mathijssen RHJ, Huitema ADR, van Erp NP, Desar IME, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Meertens M, et al. Among authors: moes djar. Clin Pharmacokinet. 2024 Jul;63(7):1045-1054. doi: 10.1007/s40262-024-01399-8. Epub 2024 Jul 16. Clin Pharmacokinet. 2024. PMID: 39012619 Free PMC article.
110 results